Literature DB >> 27115054

Imaging Outcomes of Liver Imaging Reporting and Data System Version 2014 Category 2, 3, and 4 Observations Detected at CT and MR Imaging.

Masahiro Tanabe1, Akihiko Kanki1, Tanya Wolfson1, Eduardo A C Costa1, Adrija Mamidipalli1, Marilia P F D Ferreira1, Cynthia Santillan1, Michael S Middleton1, Anthony C Gamst1, Yuko Kono1, Alexander Kuo1, Claude B Sirlin1.   

Abstract

Purpose To determine the proportion of untreated Liver Imaging Reporting and Data System (LI-RADS) version 2014 category 2, 3, and 4 observations that progress, remain stable, or decrease in category and to compare the cumulative incidence of progression in category. Materials and Methods In this retrospective, longitudinal, single-center, HIPAA-compliant, institutional review board-approved study, 157 patients (86 men and 71 women; mean age ± standard deviation, 59.0 years ± 9.7) underwent two or more multiphasic computed tomographic (CT) or magnetic resonance (MR) imaging examinations for hepatocellular carcinoma surveillance, with the first examination in 2011 or 2012. One radiologist reviewed baseline and follow-up CT and MR images (mean follow-up, 614 days). LI-RADS categories issued in the clinical reports by using version 1.0 or version 2013 were converted to version 2014 retrospectively; category modifications were verified with another radiologist. For index category LR-2, LR-3, and LR-4 observations, the proportions that progressed, remained stable, or decreased in category were calculated. Cumulative incidence curves for progression were compared according to baseline LI-RADS category (by using log-rank tests). Results All 63 index LR-2 observations remained stable or decreased in category. Among 166 index LR-3 observations, seven (4%) progressed to LR-5, and eight (5%) progressed to LR-4. Among 52 index LR-4 observations, 20 (38%) progressed to a malignant category. The cumulative incidence of progression to a malignant category was higher for index LR-4 observations than for index LR-3 or LR-2 observations (each P < .001) but was not different between LR-3 and LR-2 observations (P = .155). The cumulative incidence of progression to at least category LR-4 was trend-level higher for index LR-3 observations than for LR-2 observations (P = .0502). Conclusion Observations classified according to LI-RADS version 2014 categories are associated with different imaging outcomes. (©) RSNA, 2016 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27115054     DOI: 10.1148/radiol.2016152173

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  18 in total

1.  Longitudinal evolution of CT and MRI LI-RADS v2014 category 1, 2, 3, and 4 observations.

Authors:  Cheng William Hong; Charlie C Park; Adrija Mamidipalli; Jonathan C Hooker; Soudabeh Fazeli Dehkordy; Saya Igarashi; Mohanad Alhumayed; Yuko Kono; Rohit Loomba; Tanya Wolfson; Anthony Gamst; Paul Murphy; Claude B Sirlin
Journal:  Eur Radiol       Date:  2019-02-26       Impact factor: 5.315

2.  Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.

Authors:  Anna Darnell; Jordi Rimola; Ernest Belmonte; Enric Ripoll; Ángeles Garcia-Criado; Carla Caparroz; Álvaro Díaz-González; Ramón Vilana; María Reig; Carmen Ayuso; Jordi Bruix; Alejandro Forner
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

Review 3.  Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System.

Authors:  Sonal Krishan; Radha K Dhiman; Navin Kalra; Raju Sharma; Sanjay S Baijal; Anil Arora; Ajay Gulati; Anu Eapan; Ashish Verma; Shyam Keshava; Amar Mukund; S Deva; Ravi Chaudhary; Karthick Ganesan; Sunil Taneja; Ujjwal Gorsi; Shivanand Gamanagatti; Kumble S Madhusudan; Pankaj Puri; Shallini Govil; Manav Wadhavan; Sanjiv Saigal; Ashish Kumar; Shallini Thapar; Ajay Duseja; Neeraj Saraf; Anubhav Khandelwal; Sumit Mukhopadyay; Ajay Gulati; Nitin Shetty; Nipun Verma
Journal:  J Clin Exp Hepatol       Date:  2019-08-06

Review 4.  Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?

Authors:  Nicole E Rich; Amit G Singal
Journal:  Hepatology       Date:  2022-01-18       Impact factor: 17.425

5.  The Course of LIRADS 3 and 4 Hepatic Abnormalities as Correlated With Explant Pathology: A Single Center Experience.

Authors:  Panita Mettikanont; Anita Kalluri; Therese Bittermann; Neil Phillips; Bao-Li Loza; Mark Rosen; Evan Siegelman; Emma Furth; Peter Abt; Kim Olthoff; Abraham Shaked; Maarouf Hoteit; K Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2022-03-09

6.  Correlation of LI-RADS 3 or 4 Observations with Histopathologic Diagnosis in Patients with Cirrhosis.

Authors:  Colin Dunn; Bo Lin; Nicole E Rich; Madhukar S Patel; Purva Gopal; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2022-03-17       Impact factor: 13.576

7.  LR-3 and LR-4 Lesions Are More Likely to Be Hepatocellular Carcinoma in Transplant Patients with LR-5 or LR-TR Lesions.

Authors:  Tzu-Hao Lee; Nathan Hirshman; Diana M Cardona; Carl L Berg; Kathryn J Fowler; Mustafa R Bashir; James Ronald
Journal:  Dig Dis Sci       Date:  2022-03-07       Impact factor: 3.487

Review 8.  LI-RADS v2017 for liver nodules: how we read and report.

Authors:  Wolfgang Schima; Jay Heiken
Journal:  Cancer Imaging       Date:  2018-04-24       Impact factor: 3.909

9.  Comparison of LI-RADS v.2017 and ESGAR Guidelines Imaging Criteria in HCC Diagnosis Using MRI with Hepatobiliary Contrast Agents.

Authors:  Grzegorz Rosiak; Joanna Podgorska; Edyta Rosiak; Andrzej Cieszanowski
Journal:  Biomed Res Int       Date:  2018-07-15       Impact factor: 3.411

10.  A novel computer-aided diagnostic system for accurate detection and grading of liver tumors.

Authors:  Ahmed Alksas; Mohamed Shehata; Gehad A Saleh; Ahmed Shaffie; Ahmed Soliman; Mohammed Ghazal; Adel Khelifi; Hadil Abu Khalifeh; Ahmed Abdel Razek; Guruprasad A Giridharan; Ayman El-Baz
Journal:  Sci Rep       Date:  2021-06-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.